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Abstract 
The present studies were conducted to determine whether [3H]quinuclidinyl benzilate binding in rat colonic membranes and/or carbachol-mediated 
stimulation of particulate gnanylate cyclase were altered by changes in vitamin D status. ECs0 values for the stimulation of colonic guanylate cyclase 
by carbachol were found to be significantly greater in vitamin D-deficient rats compared to their D-sufficient counterparts. Concomitantly, the density 
of receptors (BmJ were significantly ower, and dissociation constants (K~ were significantly higher in D-deficient colonic membranes. In vitamin 
D-repleted animals, moreover, all of these aforementioned alterations were at least partially corrected. 
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1. Introduction 
Prior studies by our laboratory [1] have demonstrated 
that muscarinic agonists, such as bethanechol, rapidly 
stimulated the membrane polyphosphoinositide signal 
transduction pathway in isolated colonocytes prepared 
from vitamin D-sufficient rats. As a consequence of the 
activation of this pathway, moreover, bethanechol a so 
increased intracellular calcium, induced the transloca- 
tion of protein kinase C (PKC) from the cytosolic to 
particulate fraction and decreased intracellular pH in 
these cells [1]. In contrast o these findings in vitamin 
D-sufficient animals, bethanechol failed to elicit any of 
the aforementioned biochemical responses in vitamin 
D-deficient animals [1]. In vivo administration of 1,25- 
dihydroxycholecalciferol (1,25(OH)2D3), the major ac- 
tive metabolite of vitamin D3, for 5-7 days to vitamin 
D-deficient animals, however, almost completely re- 
stored the ability of bethanechol to induce these rapid 
colonic biochemical effects [1]. While these observations 
indicated that alterations in the vitamin D status of rats 
modulated the action of muscarinic agents on the colonic 
polyphosphoinositide signal transduction pathway, the 
mechanism(s) involved in this phenomenon were un- 
clear. 
In this regard, our laboratory has more recently dem- 
onstrated that, as assessed by pharmacologic criteria, 
only the M 3 subtype of muscarinic acetylcholine r ceptor 
(mAChR) was present on the surface of rat colonocytes 
[2]. This is of interest since M3 receptors are known to 
be coupled to membrane polyphosphoinositide turnover 
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in other cell types [3]. Moreover, we also recently demon- 
strated that this pharmacologic subtype of mAChRs was 
coupled to particulate guanylate cydase activation in rat 
colonocytes [2]. 
Based on these observations, it was the objective of the 
present experiments o determine whether alterations in 
the vitamin D status of rats, as in the case of membrane 
polyphosphoinositide turnover, also influenced the abil- 
ity of muscarinic agonists to activate colonic particulate 
guanylate cyclase. It was also of interest o determine 
whether changes in the binding properties of the M3 
receptors might account for the differences in the re- 
sponses of these second messenger systems to muscarinic 
agonists under these experimental conditions. The re- 
suits of these studies and a discussion of their signifi- 
cance serve as the basis for the present report. 
2. Experimental 
Male albino Sprague-Dawley rats, initially weighing 40-60 g, were 
used in these xperiments. All diets were obtained from ICN Biochem- 
icals (Cleveland, OH, USA) and have previously been described in 
detail [1,4]. Animals were placed either on a vitamin D-sufficient diet 
or fed a vitamin D-deficient diet and housed in a facility devoid of 
fluorescent light. The dietary content of calcium and phosphorus inthis 
diet was raised to 1.8% and 0.8%, respectively, a diet previously de- 
signed to prevent the development ofcalcinm or phosphate deficiencies, 
and/or secondary hyperparathyroidism, known complications of vita- 
min D-depfivation [1]. After 12-15 weeks, one half of the latter group 
of animals received 10 ng/100 g b.wt./day of 1,25(OH)2D 3 by osmotic 
mini pumps implanted s.c. (2001-2002, Alzet, Palo Alto, CA, USA) for 
7 days, whereas, the others received vehicle in these pumps as described 
[1]. Serum 25(OH)D3 and 1,25(OH)2D 3 levels were measured in these 
animals as previously described [1,4]. For the experiments described 
below, animals in all three groups were fasted overnight except for 
water ad libitum. 
Rats were sacrificed and their colons removed and flushed with cold 
saline containing 1 mM dithiothreitol. Colonocytes were harvested 
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using a technique which combined chelation of divalent cations and 
mild mechanical dissociation as previously described [1,4]. The isolated 
cells were then suspended in 50 mM Tris-HC1 buffer (pH 7.5) and 
homogenized, and membranes were prepared as described by Mezoff 
et al. [5]. Protein was determined in these samples by the method of 
Bradford [6]. The radiolabeled muscarinic receptor ligand, (-)- 
[3H]quinuclidinyl benzilate ([3H]QNB), was used to measure receptor 
number and affinity as described [2]. Briefly, for the saturation of 
[3I-I]QNB binding, membranes (0.1-0.2 mg protein) were incubated 
with the indicated concentrations of [3H]QNB (40.2 Ci/rnmol, New 
England Nuclear, Boston, MA) at 37"C for 45 min in 1 ml of 50 mM 
Tris-HC1 buffer (pH 7.5). At the end of these incubations, bound and 
free [3H]QNB were separated by rapid vacuum filtration as previously 
described [2]. Non-specific binding was measured in the presence of 
10/zM atropine and subtracted from total binding to obtain specific 
binding [2]. Receptor binding characteristics were then determined by 
Scatchard analysis of specifically bound [3I-I]QNB as previously de- 
scribed [2]. For the displacement of [3H]QNB binding by muscarinic 
receptor antagonists, membranes (0.1--0.2 mg protein) were incubated 
with a fixed concentration of[3I-I]QNB (0.3 nM) and indicated concen- 
trations of unlabeled atropine, pirenzepine, 4-diphenylacetoxy-N-meth- 
ylpiperidine iodine (4-DAMP) or methoctramine at 37"C in 1 ml of 
50 mM Tris-HC1 buffer (pH 7.5) for 45 rain [2]. After incubation, samples 
were filtered and [3H]QNB binding determined as described above. 
For measurement of particulate guanylate yclase activity, isolated 
colonocytes were suspended (~107 cells/ml) in Krebs-Ringer bicarbonate 
buffer (pH 7.4) containing 180 mg% glucose (KRBG buffer) and incu- 
bated in 2 ml aliquots at 37"C with the agents to be tested, or appropri- 
ate vehicles for the indicated times and concentrations. The reaction 
was terminated and membranes prepared as described previously [2]. 
Guanylate cyclase activity in these preparations was then assayed under 
conditions that were linear with respect to time and protein utilizing a 
cGMP RIA kit as described [2]. Enzyme activity was calculated as pmol 
cGMP/min/mg protein and was expressed as a percent of control (D- 
sufficient). 
Data were analyzed by analysis of variance (ANOVA) as previously 
described [2]. P < 0.05 was considered statistically significant. 
3. Results 
In agreement with prior studies f rom our laboratory 
using these diets [1,4], no significant differences were 
noted in the body weights of  the three groups of  animals 
(data not shown). Vitamin D-deficient animals as ex- 
pected, however, had very low serum 25(OH)D3 levels 
(< 5 ng/ml) and significantly lower serum levels of  
1,25(OH)eD3 (22 + 4 pg/ml, n = 14) compared with vita- 
min D-sufficient (96 + 13 pg/ml, n = 14, P < 0.01) or 
1,25(OH)2D3-repleted rats (101 + 17 pg/ml, n = 14, 
P < 0.01). 
As shown in Fig. 1, membranes prepared f rom 
isolated rat colonocytes of  all three dietary groups dem- 
onstrated saturabil ity of  specific [3H]QNB binding. 
Moreover,  as shown in the inset of  this figure, Scatchard 
analyses of  specifically-bound [3H]QNB revealed the 
presence of  only one specific subtype of  muscarinic re- 
ceptors for each of  these preparations over the ligand 
concentration tested. In agreement with our prior studies 
[2], the apparent equil ibrium dissociation constant (Kd) 
and the max imum number  of  binding sites (Bn~) of  the 
membranes prepared f rom vitamin D-sufficient rats were 
0.50 + 0.02 nM and 426 + 11 fmol/mg protein, respec- 
tively (Table 1). As can be seen in this table, the Kd value 
was significantly higher, whereas the B~,x value was sig- 
nificantly lower in membranes prepared f rom vitamin 
D-deficient rats, compared to their vitamin D-sufficient 
counterparts. Moreover,  vitamin D-repletion was found 
to totally restore the decreased Bm~ values seen in D- 
deficient membranes to control  (D-sufficient) values 
(Table 1). As shown in this table, however, D-repletion 
significantly (P < 0.05), but only partially, reduced the 
elevated Kd values seen in vitamin D-deficient colonic 
membranes toward control levels. 
To determine whether differences in vitamin D status 
might lead to alterations in the pharmacological  profile 
of  mAChRs  in the rat colon, we examined the ability of  
various selective muscarinic receptor antagonists to com- 
pete with [3H]QNB binding to rat colonic membranes 
prepared f rom animals of  all three dietary groups. The 
antagonists used included pirenzepine (Mx-selective an- 
tagonist) [7], methoctramine (M2-selective antagonist) 
[7], 4 -DAMP (M1 and M3 selective antagonist) [8,9] as 
well as atropine, a non-selective muscarinic antagonist. 
In agreement with our prior studies [2], the binding of  
[3H]QNB to colonic membranes prepared f rom vitamin 
D-sufficient rats was inhibited by these antagonists with 
the following rank order of  potencies (inhibitory con- 
stants (K.~, nM): atropine (3 .0+0.5)  = 4 -DAMP 
(5.1 + 0.7) >> pirenzepine (155 + 48) > methoctramine 
(466 + 72) (Table 1). This data is consistent with the 
existence of  the M 3 pharmacologic subtype of  mAChRs  
on rat colonocytes [2]. Furthermore,  the Ki values 
obtained, and therefore the rank order of  inhibitor po- 
tencies, was found to be similar in each of  the three 
experimental dietary groups (Table 1), indicating that 
the vitamin D status of  the animals did not alter the 
pharmacological  profile of  mAChRs  in these cells. 
In prel iminary studies, and in agreement with our 
Table 1 
[3H]QNB binding properties in rat colonic membranes a 
Experimental Bm~ Kd 
groups (fmol/mg protein) (nM) 
(nM) 
Atropine Pirenzepine 4-DAMP Methoctramine 
Vitamin D-sufficient 462 _+ 11 0.50 _+ 0.02 3.0 _+ 0.5 155 -+ 48 5.1 _+ 0.7 466 _+ 72 
Vitamin D-deficient 201 + 10" 0.88 + 0.02* 2.6 + 0.7 183 + 36 6.7 + 1.1 526 _+ 98 
Vitamin D-repleted 431 + 34 0.70 + 0.02* 2.8 + 0.8 171 + 42 6.3 + 0.8 539 _+ 84 
• Values represent mean + S.E.M. of four separate experiments for each experimental group. 
• P < 0.05 compared to vitamin D-sufficient values. 
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Fig. 1. Saturation of specific [3H]QNB binding to rat colonic membranes. Aliquots of colonic membranes prepared from vitamin D-sufficient (+), 
D-deficient (o) and 1,25(OH)2D3-repleted (<>) animals were incubated with the indicated concentrations of [3I-I]QNB for 45 min at 37"C. Non-specific 
binding was measured in the presence of 10 gM atropine and subtracted from total binding to obtain specific binding. Inset: Scatchard analysis of 
the data with the units of bound/free being fmoFmg protein/nM, and the units of bound being fmol/mg protein. Each point represents he mean of 
four separate xperiments performed in triplicate for each experimental group. 
prior findings in vitamin D-sufficient rats [2], the addi- 
tion of carbachol (10 -4 M, final concentration) to iso- 
lated colonocytes prepared from all three dietary groups 
of animals increased particulate gnanylate cyclase activ- 
ity maximally after 45 s (data not shown). Based on these 
findings, concentration-dependent studies were per- 
formed, using doses of carbachol ranging from 0.01 to 
1,000/aM, in order to obtain ECs0 values (the concentra- 
tion of agonist which increases colonic particulate 
gnanylate cyclase activity by 50%) in each of the three 
dietary groups. The ECs0 values for the stimulation of 
gnanylate cyclase by carbachol were significantly higher 
(P < 0.01) in colonic membranes prepared from D-defi- 
cient animals (7.4 + 1.1 /aM, n = 6) compared to their 
D-sufficient (0.4 + 0.1 /aM, n = 6) and D-repleted 
(1.6 + 0.2/aM, n = 6)counterparts. Moreover, the maxi- 
mal activation of particulate guanylate cyclase by car- 
bachol (1 mM, final concentration) in vitamin D-defi- 
cient and vitamin D-repleted preparations was 40 + 3% 
and 74 + 6%, respectively, of control (D-sufficient) val- 
ues. 
4. Discussion 
The present studies demonstrate for the first time that 
vitamin D-deficiency leads to an approximately 50% re- 
duction in M3 receptor density as well as a statistically 
significant decrease in the affinity of these receptors for 
muscarinic agonists in rat colonic membranes. More- 
over, in the vitamin D-deficient preparations, the effi- 
cacy of muscarinic agents to activate particulate gnanyl- 
ate cyclase is reduced. In addition, we noted a decreased 
potency of carbachol, as measured by the increase in the 
ECs0 values, to activate particulate gnanylate cyclase in 
colonocytes prepared from vitamin D-deficient rats. 
While these phenomena may, at least in part, be related 
to the aforementioned alterations in the binding proper- 
ties of the M3 receptors, these alterations in binding 
would not fully explain the total inability of carbachol 
to stimulate polyphosphoinositide turnover previously 
noted in these cells [1]. These findings, rather would 
indicate additional effects of vitamin D deficiency at the 
post-receptor level. 
In this regard, M3 mAChRs, are known to interact 
with heterotrimeric guanine nucleotide-binding (G) pro- 
teins to stimulate phosphoinositide phospholipase C 
and, thereby, increase the turnover of membrane poly- 
phosphoinositides [10]. Moreover, since the M3 subtype, 
like other subtypes of mAChRs can couple to multiple 
G proteins to induce different transduction events [11], 
it would not appear unreasonable to suggest hat the 
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activation of paniculate guanylate cyclase by carbachol 
might also involve a G protein. 
While the mechanism(s) involved in the effects of vita- 
min D-deficiency on colonic receptor- and post-receptor- 
mediated signal transduction events are unclear, they 
may involve activation of PKC. In prior studies, our 
laboratory has demonstrated that PKC appears to be 
constitutively activated in colonocytes prepared from vi- 
tamin D-deficient rats, as assessed by changes in the 
subcellular distribution of this serine/threonine kinase [1] 
and its ability to phosphorylate membrane proteins [12]. 
Moreover, this colonic activation of PKC in D-deficient 
animals was corrected by vitamin D repletion [1,12]. 
These observations are of particular interest in view of 
prior studies in neuroblastoma cells which have demon- 
strated that phorbol esters, which activate PKC, reduced 
the number of mAChRs [13-15], decreased the affinity 
of mAChRs for agonists [16], as well as attenuated recep- 
tor-mediated stimulation of polyphosphoinositide hy- 
drolysis [17,18] and cGMP production [19]. While it has 
been proposed [20] that these actions of PKC in neuro- 
blastoma cells involve phosphorylation f mAChRs, this 
has not been directly demonstrated. More recently, how- 
ever, Richardson et al. [21], using mAChRs purified 
from chicken heart, demonstrated that PKC could phos- 
phorylate mAChRs which, in turn, modulated the recep- 
tor/G-protein i teraction in an in vitro system. Based on 
these observations, further studies to determine whether 
PKC is involved in the alterations in muscarinic recep- 
tor-mediated events noted in colonocytes of vitamin 
D-deficient rats will be of interest. 
Finally, the studies of Latifpour et al. [22] deserve 
comment. These investigators, using the streptozotocin 
(STZ) model of experimental diabetes, reported that the 
B~x of M3 mAChRs in prostate plasma membranes pre- 
pared from diabetic rats was significantly decreased, but 
that insulin could prevent his receptor's down-regula- 
tion [22]. This is of considerable interest in view of earlier 
studies by our laboratory [23] and others [24], which 
documented a decrease in the serum levels of 
1,25(OH)2D3 in animals treated with STZ, secondary to 
decreased renal lg-hydroxylation. Insulin therapy, 
moreover, has been shown to prevent or correct these 
alterations in 1,25(OH)2D3 levels in this model [23,24]. It 
is, therefore, theoretically possible that alterations in the 
density of M3 receptors in the prostatic membranes of 
these animals was due, at least in part, to differences in 
their vitamin D status. Based on these findings and the 
present observations, it will, therefore, be of interest o 
determine in future studies whether the vitamin D status 
of rats can influence mAChRs-mediated signal transduc- 
tion events in other cell types besides colonocytes. 
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